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eculizumab with increased elimination half-life, allowing an
extended dosing interval from two to eight weeks. Here we
evaluate the efficacy and safety of ravulizumab in adults with
atypical hemolytic uremic syndrome presenting with
thrombotic microangiopathy. In this global, phase 3, single
arm study in complement inhibitor-naïve adults (18 years and
older) who fulfilled diagnostic criteria for atypical hemolytic
uremic syndrome, enrolled patients received ravulizumab
through a 26-week initial evaluation period. The primary
endpoint was complete thrombotic microangiopathy
response defined as normalization of platelet count and
lactate dehydrogenase and 25% or more improvement in
serum creatinine. Secondary endpoints included changes in
hematologic variables and renal function. Safety was also
evaluated. Ravulizumab treatment resulted in an immediate,
complete, and sustained C5 inhibition in all patients.
Complete thrombotic microangiopathy response was
achieved in 53.6% of patients. Normalization of platelet
count, lactate dehydrogenase and 25% or more
improvement in serum creatinine was achieved in 83.9%,
76.8% and 58.9% of patients, respectively. Improvement in
estimated glomerular filtration rate by one ormore stagewas
achieved in 68.1% of patients by day 183. No unexpected
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study initiation, including one in a patient excluded based on
eligibility criteria after the first dose) with none considered
treatment-related by the study investigator. Thus, treatment
with ravulizumab once every eight weeks resulted in rapidly
improved hematologic and renal endpoints with no
unexpected adverse events in adults with atypical hemolytic
uremic syndrome.
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A typical hemolytic uremic syndrome (aHUS) is a raredisease caused by complement dysregulation present-ing as a thrombotic microangiopathy (TMA).1 Before
the availability of terminal complement inhibition, outcomes
in patients with aHUS were poor despite the use of plasma
exchange (PE)/plasma infusion; 29% of children and 56% of
adults required renal replacement therapy or died within
1 year2 and 48% of children and 67% of adults suffered end-
stage renal disease or death at 3 years.3
Eculizumab (Soliris; Alexion Pharmaceuticals, Inc., Boston,
MA) was approved for the treatment of patients with aHUS in
2011,4,5 with efficacy and safety shown across 4 prospective
clinical trials,6–10 and additional data from nearly a decade of
registry and nontrial patient data.11,12 Although highly effec-
tive in treating aHUS, eculizumab requires a standard treat-
ment regimen of intravenous infusions every 2 weeks in
patients with a body weight of 10 kg or greater.131287
Figure 1 | Patient disposition. aBoth patients were discontinued from the trial owing to positive Shiga toxin–producing Escherichia coli
hemolytic uremic syndrome; 1 patient died after study discontinuation from cerebral arterial thrombosis. bTreatment-emergent adverse events
(AEs) leading to study discontinuation were autoimmune hemolytic anemia, intracranial hemorrhage (resulting in patient death), and immune
thrombocytopenic purpura. Major protocol deviation was the receipt of plasma exchange. aHUS, atypical hemolytic uremic syndrome; TMA,
thrombotic microangiopathy.
c l i n i ca l t r i a l E Rondeau et al.: Ravulizumab efficacy and safety in adults with aHUSRavulizumab (Alexion Pharmaceuticals, Inc.), a humanized
monoclonal antibody that blocks terminal complement acti-
vation at C5, was engineered from eculizumab, resulting in a
molecule that targets the same epitope as eculizumab with an
extended half-life.14 Two amino acid substitutions were made
to preserve high binding affinity to C5 in serum at pH 7.4 and
to permit dissociation of C5 from ravulizumab in the acidified
endosome at pH 6.0. Two further amino acid substitutions
were made to enhance affinity for the neonatal Fc receptor at
pH 6.0 and increase antibody recycling. Overall, these changes
lead to an increased duration of terminal complement inhi-
bition and a greater than 4-fold longer mean elimination half-
life (51.8 d) compared with eculizumab through additional
rounds (recycling) of binding and neutralization of C5.14
A reduction in dosing frequency without sacrificing the
immediate and complete C5 inhibition and resolution of
TMA is expected to improve patient quality of life by reducing
infusion burden and other potential consequences of repeated
venous punctures and infusions.15,16 The objective of the
current analysis was to evaluate the efficacy and safety of
ravulizumab in adult patients with aHUS.
RESULTS
Patient characteristics
Fifty-eight complement inhibitor–naive adults were enrolled
and received 1 or more doses of ravulizumab. Two patients
discontinued the study after the first dose because of ineli-
gibility per protocol (both tested positive for Shiga toxin–1288producing Escherichia coli hemolytic uremic syndrome
[STEC-HUS]) and were excluded from the full analysis set.
Forty-nine patients completed the 183-day initial evaluation
period and 7 patients discontinued (Figure 1). The full
analysis set comprised 56 patients with a median age of
40.1 years (range, 19.5–76.6 yr), of whom 37 (66.1%) were
women, 8 (14.3%) were immediately postpartum, and 8
(14.3%) had received a prior kidney transplant (Table 1).
Forty-eight patients (82.8%) had pretreatment PE/plasma
infusion related to the current TMA before their first dose of
ravulizumab. Before screening, 27 (48.2%) patients had been
in intensive care for a mean duration of 10.1 days (10.0 d).
At baseline, 92.9% had extrarenal symptoms (Supplementary
Table S1). Baseline laboratory values are shown in Table 1 and
the earliest pretreatment laboratory values for the current
manifestation are shown in Supplementary Table S2.
Primary end point
During the initial evaluation period, 30 patients (53.6%) met
the primary end point of complete TMA response (Table 2).
The median time to complete TMA response was 86.0 days
(95% confidence interval, 42.0, upper limit was not evaluable)
days (Figure 2).
Hematologic end points
Forty-seven (83.9%) patients achieved platelet count
normalization. The median increase in platelet count from
baseline to day 183 was 125.0 109/l (range, –126 109/lKidney International (2020) 97, 1287–1296
Table 1 | Baseline demographics and disease characteristics
Variable, n (%), unless stated
Overall
(N [ 56)
Median age at the time of the first infusion, yr (range) 40.1 (19.5–76.6)
Category
$18 to <30 yr 11 (19.6)
$30 to <40 yr 17 (30.4)
$40 to <50 yr 15 (26.8)
$50 to <60 yr 5 (8.9)
$60 yr 8 (14.3)
Sex, female 37 (66.1)
Race
Asian 15 (26.8)
White 29 (51.8)
Undisclosed 8 (14.3)
Other 4 (7.1)
Patients with prior manifestations of aHUS 3 (5.4)
Median age at time of the first aHUS symptom, yr
(range)
40.1 (9.3–76.6)
Median time from first aHUS symptom to first dose of
ravulizumab, mo (range)
0.28 (0–215.0)
Kidney transplant before entering the study 8 (14.3)
Postpartum 8 (14.3)
eGFR category at baseline
1 0 (0.0)
2 3 (5.4)
3a 1 (1.8)
3b 2 (3.6)
4 9 (16.1)
5 40 (71.4)
Missing 1 (1.8)
Dialysis within 5 d of the first dose 29 (51.8)
PE/PI before the first dose and related to current TMAa 48 (82.8)
Baseline laboratory values, median (range)b
Platelets, 109/l 95.3 (18–473)
LDH, U/l 508 (230–3249)
Serum creatinine, mmol/la 284 (51–1027)
eGFR, ml/min per 1.73 m2 10 (4–80)
Hemoglobin, g/l 85 (60.5–140)
Normalization of platelet count and/or LDH at
baseline
26 (46.4)
Patients with $1 identified pathogenic variant or
autoantibodyc,d
8 (20.5)
C3 1 (2.6)
CD46 2 (5.1)
CFB 1 (2.6)
CFH 2 (5.1)
CFH autoantibody 2 (5.1)
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; eGFR, esti-
mated glomerular filtration rate; LDH, lactate dehydrogenase; PE, plasma exchange;
PI, plasma infusion; TMA, thrombotic microangiopathy.
aSafety set, N ¼ 58.
bBaseline values may be after PE/PI in some patients.
cNumber of patients tested, n ¼ 39.
dOne additional patient had a CFH autoantibody; however, this patient was not
tested for genetics. In total, 3 of 52 patients tested for CFH autoantibodies were
positive.
Table 2 | Complete TMA response, individual components,
and hematologic normalization through initial evaluation
period of 26 weeks
Variable
Overall
(N [ 56)
Complete TMA response 30 (53.6)
95% CI 39.6–67.5
Hematologic normalizationa 41 (73.2)
95% CI 60.7–85.7
Platelet count normalization 47 (83.9)
95% CI 73.4–94.4
LDH normalization 43 (76.8)
95% CI 64.8–88.7
$25% improvement in serum creatinine from baseline 33 (58.9)
95% CI 45.2–72.7
CI, confidence interval; LDH, lactate dehydrogenase; TMA, thrombotic
microangiopathy.
aDefined as normalization of both LDH and platelet count.
Data shown as n (%). 95% CIs for the proportion are based on the asymptotic
Gaussian approximation method with a continuity correction.
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70.5 109/l (range, –139 109/l to þ629 109/l) by day 8.
Lactate dehydrogenase (LDH) normalization was reached in
43 (76.8%) patients. The median decrease in LDH from
baseline to day 183 was 310.8 U/l (range, 3072 U/l to þ9 U/l)
(Figure 3b). Forty patients (71.4%) achieved an increase in
hemoglobin of 20 g/l or more between baseline and day 183.
A substantial median increase in hemoglobin from baseline to
day 183 of 35.0 g/l (range, –9 g/l to þ69 g/l) (Figure 3c) wasKidney International (2020) 97, 1287–1296observed. Hemoglobin rapidly improved by day 15, with a
median change of 0.5 g/l (range, –41 g/l to þ34 g/l).
Renal end points
Renal function (estimated glomerular filtration rate [eGFR])
substantially improved from baseline, with a median increase
of 29.0 ml/min per 1.73 m2 (range, –13 ml/min per 1.73 m2
to þ108 ml/min per 1.73 m2) to day 183 and had increased
substantially by day 15 (Figure 3d). Dialysis was discontinued
in 17 of 29 patients (58.6%) who were on dialysis at baseline by
a median time of 30 days. Of the 27 patients who were not on
dialysis at baseline, 21 (77.8%) remained off dialysis at the last
available follow-up evaluation (which may have occurred after
day 183). Improvement in eGFR (changed to a less severe
eGFR category between baseline and day 183) was seen in 32 of
47 patients (68.1%) with available data (Figure 4).
Quality of life end points
Forty-four patients had Functional Assessment of Chronic
Illness Therapy–Fatigue data at both baseline and day 183. At
day 183, a clinically meaningful improvement ($3-point in-
crease) in the Functional Assessment of Chronic Illness
Therapy–Fatigue score17 was observed in 37 of 44 (84.1%) pa-
tients with available data at both baseline and day 183, and the
median increase was 20.0 points (range, –16 toþ48) (Figure 5).
Pharmacokinetic and pharmacodynamic analysis
After initiation of weight-based dosing of ravulizumab,
steady-state serum concentrations were achieved. Weight-
based dosing resulted in maximal steady state and trough
exposures as predicted with no unexpected pharmacokinetic
findings (Supplementary Figure S1). Free C5 in serum
results showed that ravulizumab treatment achieved imme-
diate, complete, and sustained terminal complement inhibi-
tion as defined by free C5 in serum concentrations less than
0.5 mg/ml (Figure 6). No resistance to C5 was noted, with the
majority of postdose samples (852 of 856; 99.5%) having
shown complete C5 inhibition.1289
Figure 2 | Kaplan-Meier graph showing time to complete thrombotic microangiopathy (TMA) response. Patients who did not have a
response were censored on the day of their last study visit, or at study discontinuation. BL, baseline.
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Across the 58 patients in the safety set (all received $1 dose),
ravulizumab treatment resulted in no unexpected adverse
events through a median (range) follow-up of 39.6 months
(0.6–81.1 months). All patients experienced 1 or more
adverse events (AEs) during the study. Twenty patients
(34.5%) experienced treatment-related AEs, most commonly
headache, diarrhea, and vomiting (Tables 3 and 4). Thirty
patients (51.7%) experienced serious AEs (SAEs), most
commonly hypertension and pneumonia (Table 5). Three
patients (5.2%) discontinued study treatment and withdrew
from the study because of an SAE (autoimmune hemolytic
anemia, intracranial hemorrhage, and immune thrombocy-
topenic purpura). No meningococcal infections were re-
ported. One patient tested positive for a transient low-titer,
non-neutralizing antibody to the study drug at one time point
with no effect on efficacy, safety, or pharmacokinetics/
pharmacodynamics.
Four patients (6.9%) died during the study (further details
are shown in Supplementary Table S3). Causality assessment
by the treating investigator deemed each death as unrelated to
the study drug. Three deaths were the result of fatal treatment-
emergent AEs: 2 from septic shock and 1 from cerebral hem-
orrhage. One patient died of a pretreatment SAE (cerebral
artery thrombosis). This patient was also discontinued per
protocol because of a positive STEC test, with the result ob-
tained after the first dose was administered. This patient was
not included in the efficacy analysis (full analysis set). Three of
the deaths occurred within the first month of treatment.
DISCUSSION
This was a prospective phase 3 trial evaluating the efficacy and
safety of ravulizumab in adults with aHUS. The study showed
that ravulizumab rapidly resolved TMA caused by aHUS with
53.6% of patients reaching the primary end point of complete
TMA response. Ravulizumab was effective in inducing he-
matologic remission (platelet count and LDH normalization
were achieved in 83.9% and 76.8% of patients, respectively)
and improvement in renal function (improvement in eGFR1290category in 68.1% of patients with available data) with no
unexpected adverse events. From a clinical perspective, it
should be noted that the primary end point, complete TMA
response, is a stringent research outcome designed to measure
a simultaneous complete hematologic and renal improvement
in patients with TMA. Platelets and LDH, which are the most
frequent variables used for evaluating treatment response in
patients with aHUS,18 rapidly and dramatically improved
after ravulizumab treatment in most patients (73.2%).
Ravulizumab was engineered from eculizumab, and the
efficacy and safety of eculizumab was established previously
through clinical studies and real-world data.6,8 The current
study was an open-label single-arm not designed as a com-
parison study to eculizumab; thus direct comparison is
inappropriate. Some context for these ravulizumab results is
provided by the results from these earlier eculizumab studies
(Supplementary Table S4). In terms of end points and pop-
ulation, the eculizumab study with the fewest differences is
the adult C10-004 study (Fakhouri et al.6; NCT01194973), an
open-label, clinical trial of eculizumab in adult patients with
aHUS, which also assessed improvement in hematologic pa-
rameters (platelet count and LDH) and renal function. It
should be noted that there are important study design dif-
ferences that may impact data interpretation, including the
allowed use of PE during the initial treatment period for C10-
004 but not in the current study, and the definition of baseline
dialysis, which was more restrictive in the current study,
making direct comparisons of these outcomes difficult.
In C10-004, the end point identical to complete TMA
response (termed “modified complete TMA response”) was
achieved in a similar proportion (56.1%) of patients to the
current study. Both ravulizumab and eculizumab dramatically
improved the platelet count after 1 week.6 The median time to
complete TMA response was shorter in the eculizumab trial
than in the current study (86 d). Fatigue also rapidly
improved in both trials.
In terms of renal response, the proportion of patients with
an improvement in eGFR category ($15 ml/min per 1.73 m2)
between baseline and day 183 was 68.1% in the current study,Kidney International (2020) 97, 1287–1296
Figure 3 | Observed laboratory values over time. (a) Platelet count, (b) lactate dehydrogenase, (c) hemoglobin, and (d) estimated
glomerular filtration rate (eGFR). Data are shown as mean (error bars, 95% confidence interval). BL, baseline.
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eGFR categories 
at baseline (N=47)a
eGFR categories at day 183
1
(≥90)
2 
(60–89)
3a 
(45–59)
3b 
(30–44)
4 
(15–29)
5 
(<15)
1 (≥90) 0 (0.0)
2 (60–89) 3 (6.4) 2 (4.3) 1 (2.1)
3a (45–59) 1 (2.1) 1 (2.1)
3b (30–44) 2 (4.3) 2 (4.3)
4 (15–29) 7 (14.9) 1 (2.1) 3 (6.4) 1 (2.1) 2 (4.3)
5 (<15) 34 (72.3) 6 (12.8) 6 (12.8) 3 (6.4) 3 (6.4) 5 (10.6) 11 (23.4)
Figure 4 | Change in estimated glomerular filtration rate (eGFR) categories from baseline to day 183. Data presented as n (%).
aRepresents the number of patients with available eGFR category data at both baseline and day 183. eGFR categories are shown in ml/min per
1.73 m2. Green cells represent improvement from baseline to day 183; red cells represent worsening, and white cells represent no change.
c l i n i ca l t r i a l E Rondeau et al.: Ravulizumab efficacy and safety in adults with aHUSand was 53.7% in the eculizumab trial. The improvement in
eGFR was substantial in both studies (35 and 29 ml/min per
1.73 m2, respectively). A 25% or more decrease in serum
creatinine concentration from baseline was observed in an
identical proportion of patients (59% in both studies). With
the more restrictive definition of dialysis at baseline used in
the current study, the proportion of patients on dialysis at
baseline in whom dialysis was able to be discontinued by day
183 still was considerable (58.6%). The broader definition
used in the C10-004 eculizumab study resulted in 83% of
patients defined as on dialysis at baseline being able to dis-
continue. In patients not on dialysis at baseline, an almost
identical proportion of these patients remained off dialysis
(77.8% in this trial and 76.5% in the eculizumab trial). The
high proportion of renal improvement is probably owing to
the rapid time to treatment in both studies (median, 0.28 mo
from first reported aHUS symptom to the first dose in the
current study; median, 0.79 mo from diagnosis to screening
in the eculizumab trial). The time to eculizumab treatment
has been confirmed to be important in recovering renal
function, with earlier treatment leading to greater renal re-
covery, as shown in a recent pooled analysis.19 Furthermore,
patients who achieved a complete TMA response in theFigure 5 | Functional Assessment of Chronic Illness Therapy (FACIT)–
shown as mean (error bars, 95% confidence interval).
1292current study were treated earlier than patients who did not
achieve a complete TMA response (0.23 and 0.61 mo from
first aHUS symptom to the first dose, respectively). In sum-
mary, the current study shows that patients treated with
ravulizumab can rapidly achieve a clinically meaningful
response maintained throughout the 8-week dosing interval.
All patients enrolled in this study experienced 1 or more
AEs, with treatment-related AEs occurring in 34.5% of pa-
tients and SAEs occurring in 51.7% of patients. Two of the 7
patients who were discontinued from this study had reported
SAEs of immune thrombocytopenic purpura and autoim-
mune hemolytic anemia. Although these patients had aHUS
(by prespecified inclusion/exclusion criteria), they also had
concomitant conditions unresponsive to complement inhi-
bition. In the previous trials of eculizumab, AEs were re-
ported in 90.9% to 100% of patients, and SAEs were reported
in 43.9% to 100%.6–8
A recent 10-year analysis of pharmacovigilance data
confirmed that the key risk remains meningococcal infection
in patients treated with eculizumab.20 However, in the current
study, no meningococcal infections were reported, consistent
with previous trials7,8; 2 meningococcal infections (4.9%)
were noted in 1 of the eculizumab trials (C10-0046).Fatigue score over time from baseline (BL) to day 183. Data are
Kidney International (2020) 97, 1287–1296
Figure 6 | Pharmacodynamics of free C5 in serum concentration box plots over time (semi-log scale). Horizontal line is drawn at free C5
at 0.5 ug/ml to denote the threshold for complete terminal complement inhibition. The horizontal line in the middle of each box indicates the
median, a diamond indicates the mean, and the top border and the bottom border of the boxes mark the 75th and 25th percentiles,
respectively. The whiskers represent the highest and lowest values within 1.5  the interquartile range from the lower quartile and upper
quartile. Outliers are represented by an asterisk beyond the whiskers.
E Rondeau et al.: Ravulizumab efficacy and safety in adults with aHUS c l i n i ca l t r i a lFour deaths were reported in the current study, each
determined by the treating investigator to be unrelated to the
study drug. One patient enrolled and treated with 1 dose of
ravulizumab was diagnosed initially with aHUS but later
confirmed as STEC-HUS and excluded from the efficacy
analysis. This patient died as a result of a SAE (cerebral
arterial thrombosis) that occurred before treatment with
ravulizumab. Three deaths were the result of non–treatment-
related SAEs of secondary causes (2 cases of septic shock and
1 case of intracranial hemorrhage). There were no deaths in
the eculizumab trials during the initial 26-week evaluation
period. However, deaths unrelated to the study drug in this
very severe disease have been reported during follow-up
evaluation, mainly attributed to concomitant disease or
conditions, such as those observed in this study.21 TheTable 3 | Summary of adverse events reported
Category
Overall (N [ 58)
n (%) Events
Any AE 58 (100.0) 818
Treatment-related 20 (34.5) 58
Not treatment-related 58 (100.0) 760
Any SAE 30 (51.7) 71
Fatal TEAE 3 (5.2) 3
Fatal pretreatment SAE 1 (1.7) 1
Meningococcal infection 0 (0.0) 0
AE severity
Grade 1 54 (93.1) 454
Grade 2 46 (79.3) 223
Grade 3 31 (53.4) 116
Grade 4 14 (24.1) 22
Grade 5 3 (5.2) 3
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events;
MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event;
TEAE, treatment-emergent adverse event.
AE terms are as reported by the treating investigator. Patients evaluated for safety
include all patients who received 1 or more doses of the study drug. AEs were coded
using MedDRA version 21.0 and the severity of AEs was graded using CTCAE version
4.03. Grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening;
grade 5, death.
Kidney International (2020) 97, 1287–1296patients in this study who died had significant comorbidities
and presented in a critical state, with 3 of them receiving
mechanical ventilation at baseline. Of the 222 patients treated
with ravulizumab across the paroxysmal nocturnal hemo-
globinuria phase 3 trials, no deaths were reported.22,23
However, unlike paroxysmal nocturnal hemoglobinuria,
which can be confirmed by laboratory variables, aHUS is a
clinical diagnosis that relies on exclusion of other condi-
tions,24 so it is possible that some patients with additional
conditions similar to aHUS were enrolled. In this study, 39
patients had undergone mutational analysis/complement
antibody testing and 20.5% had a confirmed pathogenic
variant or autoantibody finding. In the literature, pathogenic
variants are found in only approximately 60% to 70% of
patients with a diagnosis of aHUS, making the proportion
relatively low in this cohort.2,3 However, genetic testing was
not performed on all patients in this cohort and was evaluated
by whole-exome sequencing, which potentially could miss
abnormal fusion proteins (notably between complement
factor H and complement factor H–related protein) andTable 4 | Most frequent treatment-emergent adverse events
Adverse event term
Overall (N [ 58)
n (%) Events
Headache 21 (36.2) 28
Diarrhea 18 (31.0) 24
Vomiting 15 (25.9) 18
Hypertension 13 (22.4) 20
Nausea 13 (22.4) 16
Urinary tract infection 10 (17.2) 21
Dyspnea 10 (17.2) 13
Arthralgia 10 (17.2) 12
Pyrexia 10 (17.2) 11
Cough 10 (17.2) 10
Hypokalemia 9 (15.5) 18
Edema peripheral 9 (15.5) 13
Events occurring in more than 15% of patients are listed. Adverse event terms are as
reported by the treating investigator. Patients evaluated for safety include all pa-
tients who received 1 or more doses of the study drug.
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Table 5 | Most frequent treatment-emergent serious adverse
events
Adverse event term
Overall (N [ 58)
n (%) Events
Hypertension 3 (5.2) 5
Pneumonia 3 (5.2) 3
Malignant hypertension 2 (3.4) 5
Urinary tract infection 2 (3.4) 4
Septic shock 2 (3.4) 2
aHUS 2 (3.4) 2
aHUS, atypical hemolytic uremic syndrome.
Events occurring in more than 3% of patients are listed. Adverse event terms are as
reported by the treating investigator. Patients evaluated for safety include all pa-
tients who received 1 or more doses of the study drug.
c l i n i ca l t r i a l E Rondeau et al.: Ravulizumab efficacy and safety in adults with aHUSmutations in short consensus repeats 20 of complement
factor H. Although a positive genetic test can help to confirm
a previously clinically diagnosed case of aHUS, it is not
needed to make the diagnosis of aHUS or to commence
treatment. A clinical differential diagnosis remains the pri-
mary method of establishing a diagnosis of aHUS.
There were several additional limitations to this study.
Given that aHUS often requires triggering conditions to
manifest and that the differential diagnostic process can be
lengthy,24,25 there is a possibility that some patients had
TMAs that were not a result of complement dysregulation.
However, at presentation, they met the study inclusion
criteria based on the information available at that time. In
addition, because of the primary efficacy end point requiring
several outcomes to be met over a 28-day period, any patients
discontinuing the study within 28 days of enrollment could
not meet this end point, regardless of whether any outcomes
were met. Any effect of these limitations on the study data are
likely to be minimal.
Conclusion
Ravulizumab was evaluated in this trial in a broad population
of adult patients with aHUS, including patients with trig-
gering conditions. Treatment with ravulizumab in adult pa-
tients rapidly resolved acute and life-threatening,
complement-mediated TMA caused by aHUS, with imme-
diate and complete terminal complement inhibition sustained
throughout the initial evaluation period of 26 weeks.
Furthermore, patients treated with ravulizumab experienced
no unexpected adverse events. Treatment with ravulizumab
will provide meaningful benefits for patients and their fam-
ilies in terms of reducing the treatment burden, with in-
fusions limited to once every 8 weeks. The results from this
study support the use of ravulizumab in adult patients with
aHUS; ravulizumab has been approved in the United States
for the treatment of adults and children (age, $1 mo) with
aHUS. A clinical trial assessing the efficacy and safety in pe-
diatric patients is ongoing.
METHODS
Trial oversight and study design
ALXN1210-aHUS-311 (NCT02949128) is a phase 3, single-arm,
multicenter study to evaluate the efficacy and safety of1294ravulizumab administered by intravenous infusion to adults
(age, $18 yr) with aHUS naive to complement inhibitor treatment.
The protocol was approved by the Institutional Review Board or
Independent Ethics Committee at each participating center, and the
study was conducted in accordance with the Declaration of Helsinki
and the Council for International Organizations of Medical Sciences
International Ethical Guidelines.
The study consisted of an initial evaluation period of 26 weeks.
The administration was via intravenous infusion at a maximum
infusion rate of 276 to 333 ml/h, with dosage based on body weight.
An intravenous loading dose of 2400 mg, 2700 mg, and 3000 mg was
administered in patients at least 40 to less than 60 kg, at least 60 to
less than 100 kg, and 100 kg or more, respectively, on day 1 and
maintenance doses of 3000 mg, 3300 mg, and 3600 mg, respectively,
on day 15, and then every 8 weeks thereafter. After the initial eval-
uation period, patients were eligible to continue in an extension
period for up to 4.5 years. Baseline was defined as the period from
screening up to before the point of the first study drug infusion,
including day 1.
Study population
Patients age 18 years and older and weighing at least 40 kg with
evidence of active TMA (thrombocytopenia, hemolysis, and kidney
dysfunction) after exclusion of thrombotic thrombocytopenic pur-
pura and STEC-HUS per diagnostic guidelines for aHUS24 were
included. Patients could meet the platelet and LDH criteria
(<150 109 and $1.5  upper limit of normal, respectively) based
on results from local laboratories, but the serum creatinine criteria
($upper limit of normal) must have been confirmed by the central
laboratory at baseline. Postpartum or renal transplant patients
were permitted but must have had either persistent evidence of TMA
(3 d after childbirth or 4 d after modifying dosing of calcineurin
inhibitors or mammalian target of rapamycin inhibitors, respec-
tively) or a prior history of aHUS. Patients must have received
meningococcal vaccination according to local and national guide-
lines at the time of commencing therapy and also were required to
receive treatment doses of antibiotics from the time of the first dose
of ravulizumab until at least 2 weeks after vaccination.
Patients with a deficiency of a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13 (activity <5%,
suggestive of thrombotic thrombocytopenic purpura); known STEC-
HUS; evidence of Streptococcus pneumoniae–related HUS, with a
positive direct Coombs test and/or a positive S pneumoniae culture
were excluded. Patients receiving immunosuppressive therapies were
excluded unless they were part of an established post-transplant
antirejection regimen, the patient had confirmed anticomplement
antibodies, or if steroids were being used for a different condition.
Patients receiving PE/plasma infusion for a period of 28 days or
longer before screening were excluded. PE/plasma infusion was
allowed up to, but not after, the first dose of ravulizumab. Patients on
chronic dialysis at screening (defined as dialysis on a regular basis for
end-stage renal disease) also were excluded. Complete inclusion and
exclusion criteria are shown in the Supplementary Inclusion and
Exclusion Criteria.
Efficacy end points
The primary efficacy end point was complete TMA response through
the 26-week initial evaluation period. The criteria for complete TMA
response were platelet count normalization ($150  109/l), LDH
normalization (#246 U/l), and 25% or better improvement in serum
creatinine from baseline. Patients had to meet all TMA criteriaKidney International (2020) 97, 1287–1296
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ments obtained at least 28 days apart, and at any measurement in
between. This end point was used as a secondary outcome in previous
phase 2 studies of eculizumab (but termed “modified complete TMA
response” by Fakhouri et al.6 [NCT01194973]). Platelet values ob-
tained on the day of a platelet transfusion through 3 days after the
transfusion were excluded from all analyses. All serum creatinine
values obtained during dialysis were excluded from all analyses. When
a patient was on dialysis at baseline, the first valid baseline creatinine
value used was the first assessment 6 days or more after dialysis. If a
patient was on dialysis throughout the initial evaluation period, the
baseline creatinine value was not calculated and the component of the
response for improvement in renal function was not achieved.
The secondary objectives of the study included the analysis of
dialysis requirement status (patients were considered as being on
dialysis at baseline if dialysis occurred within 5 days before rav-
ulizumab initiation); time to complete TMA response; change in
eGFR; eGFR category, as evaluated by eGFR at select target days;
change in hematologic variables (platelets, LDH, hemoglobin); and
change in quality of life, as measured by the Functional Assessment of
Chronic Illness Therapy–Fatigue version 4. Exploratory analysis of
pathogenic complement genetic variants was performed in consenting
patients using whole-exome sequencing on the Novaseq 6000 plat-
formwith a 2 150-bp paired-endmodule (Illumina, Inc., SanDiego,
CA). Pathogenesis was determined as shown in the Supplementary
Whole-Exome Sequencing and Assessment of Variant Pathogenicity
Process. The pharmacokinetic and pharmacodynamic end points
were changes in serum ravulizumab concentration and free C5 in
serum concentrations over time (Supplementary Description of Free
C5 Assay). Free C5 less than 0.5 ug/ml is recognized as correlating
with complete terminal complement inhibition.5,26
Safety end points
The safety and tolerability of ravulizumab were evaluated by physical
examinations, vital signs, electrocardiograms, laboratory assess-
ments, and incidence of AEs and SAEs. AEs were coded using
MedDRA version 21.0 (MedDRA MSSO, McLean, VA) and the
severity of AEs was graded using CTCAE version 4.03 (National
Cancer Institute, Bethesda, MD). The proportion of patients who
developed antidrug antibodies also was assessed.
Statistical analysis
This study was not powered for statistical comparisons; the sample size
was based strictly on achieving a desired level of estimation precision. A
sample size of 55 was deemed sufficient for achieving the estimation
precision and complete safety information. Demographics and baseline
characteristics of all enrolled patients were summarized for the full
analysis set and the safety set (patients who received$1 dose of the study
drug, including patients who later were excluded). Efficacy analyses were
performed on the full analysis set.
The primary efficacy analysis for complete TMA response
was summarized by the number and proportion of responders with a
2-sided 95% confidence interval.
Secondary analyses included the proportion of patients requiring
dialysis over time. For the secondary analysis of time to complete
TMA response, a Kaplan-Meier curve was generated. Kidney func-
tion, evaluated by eGFR, was summarized using descriptive statistics
for observed value and change from baseline. Serum creatinine
values of patients on dialysis were excluded and the eGFR was set to
10 ml/min per 1.73 m2 in these cases. The eGFR category, defined
using Kidney Disease Improving Global Outcomes chronic kidneyKidney International (2020) 97, 1287–1296disease criteria eGFR value parameters, was summarized over time
with the proportion of patients who improved, worsened, and stayed
the same compared with baseline.27 Hematologic laboratory
variables were summarized using descriptive statistics for the
observed value and change from baseline. The proportion of patients
achieving a hemoglobin response (an increase in hemoglobin
from baseline [$20 g/l] over at least 2 consecutive
measurements $28 days apart) were summarized over time with a
2-sided 95% confidence interval for each post-baseline time point.
The proportion of patients with at least a 3-point improvement
according to the Functional Assessment of Chronic Illness Therapy–
Fatigue also were summarized.
Pharmacokinetic/pharmacodynamics analysis was performed in
all patients who had received at least 1 infusion of the study drug and
had evaluable data.
Safety analyses were performed for the safety set. All AEs were
summarized by system organ class and preferred term.APPENDIX
311 Study Group Members
Sunil Babu (Principle Investigator [PI]), Fort Wayne Medical Oncology and
Hematology, Fort Wayne, IN, USA; Nilufer Broeders (PI) and Nicole Lietar,
Université libre de Bruxelles – Erasme, Brussels, Belgium; Fiona Brown (PI),
Monash Medical Centre, Clayton, Victoria, Australia; Philip Campbell (PI),
Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia;
Paramit Chowdhury (PI) and Theo Kasimatis, Guy’s Hospital, Guy’s and St
Thomas’ NHS Foundation Trust, London, UK; Lino Cirami (PI), Leonardo Caroti,
and Guilia Antognoli, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy;
Yahsou Delmas (PI), Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France;
Vladimir Dobronravov (PI), FSBEI HE I.P. Pavlov SPbSMU MOH, St. Petersburg,
Russia; Anja Gaeckler (PI), Universitaetsklinikum Essen, Essen, Germany; Cyril
Garrouste (PI), Clermont-Ferrand Hôpital, CHU Gabriel-Montpied, Clermont-
Ferrand, France; Gregory Greenwood (PI), Novant Health Forsyth Medical
Center, Winston-Salem, NC, USA; Siân Griffin (PI), University Hospital of Wales,
Wales, UK; Chiu-Ching Huang (PI) and I-Ru Chen, China Medical University
Hospital, Taichung City, Taiwan; Susan Huang (PI), London Health Sciences
Center, London, Ontario, Canada; Jin Seok Kim (PI), Severance Hospital, Yonsei
University Health System, Seoul, Republic of Korea; Gaetano La Manna (PI),
Giorgia Comai, and Maria Cappuccilli, Azienda Ospedaliera Universitaria
Policlinico Sant’Orsola Malpighi, Bologna, Italy; Moglie Le Quintrec (PI) and
Guillaume Jeantet, Hopital Lapeyronie, CHU De Montpellier, Montpellier,
France; Iino Fumie, Saitama Medical University, Iruma, Japan; Yosu Luque,
Hôpitaux de Paris 6, Sorbonne Université, Paris, France; Jan Menne, Hannover
Medical School, Hannover, Germany; Johan Morelle (PI) and Eric Goffin,
Cliniques Universitaires Saint-Luc, Brussels, Belgium; Anja Muhlfeld (PI),
Universitaetsklinikum Aachen, AöR, Medizinische Klinik II, Aachen, Germany;
Shashi Nagaraj (PI) and Gowthami Arepally, Duke University, Durham, NC, USA;
Doyeun Oh (PI), CHA Bundang Medical Center, CHA University, Seongnam,
Gyeonggi-do, Republic of Korea; Masayoshi Okumi (PI), Tokyo Women’s
Medical University Hospital, Tokyo, Japan; Manuel Praga Terente (PI), Elena
Gutierréz, and Paola Rodriguez, Hospital Universitario 12 de Octubre, Madrid,
Spain; Francois Provot (PI), Hôpital Claude Huriez, Chu de Lille, Lille, France; Ulf
Schönermarck (PI) and Michael Fischereder, Medizinische Klinik IV, Klinikum
der Universität, LMU, Munich, Germany; Natalia Ramos Terrada, University
Hospital Vall d’Hebron, Barcelona, Spain; Barbara Seitz-Polski (PI), Guillaume
Favre, and Sonia Boyer-Suavet, Hôpital Pasteur, CHU de Nice, Nice, France;
Maria Vinogradova (PI) and Tatiana Kirsanova, FSBI of the Ministry of
Healthcare of Russia, Moscow, Russia; and Edwin K.S. Wong, Royal Victoria
Hospital, Newcastle University, Newcastle upon Tyne, UK.DISCLOSURE
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